Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of glycopyrronium bromide and neostigmine methylsulfate injection for reversal of residual neuromuscular block
CTR20251161Phase 3Completed
- Sponsor
- Nanjing Zhengke Pharmaceutical
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of neostigmine + glycopyrrolate in Postoperative residual curarization (PORC), sponsored by Nanjing Zhengke Pharmaceutical. Started Apr 2025; status: completed.
02
Drugs
neostigmine + glycopyrrolate
03
Conditions
Postoperative residual curarization (PORC)
Beyond the preview
Go deeper on CTR20251161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251161.